Article Abstract

Editorial: early PSA-testing after radical prostatectomy—the truth behind the scenes

Authors: Julian Hanske, Florian Roghmann, Joachim Noldus, Marko Brock

Abstract

Adequate treatment of localized prostate cancer (PCa) remains challenging. Data from the U.S. National Cancer Institute reveals that PCa accounts for 9.9% of all new cancer diagnoses and 5.2% of all cancer deaths, accounting for 174,650 new cases and 31,620 deaths in 2019 (1). This data shows still a definite necessity for wide-ranging diagnostic, treatment, and follow-up options.